Introduction
============

Cervical cancer is the second most common malignancy worldwide and the third most frequent cause of cancer death among women. An estimated 140,000 new cases of cervical cancer occur annually in the People's Republic of China, which accounts for one-third of all the world's new cases of cervical cancer.[@b1-ppa-7-1061] From 2003 to 2007, however, morbidity increased sharply from 7.14/100,000 to 11.74/100,000 due to the increased rates of infection with human papilloma virus, which has attracted extensive attention in the People's Republic of China.[@b2-ppa-7-1061]--[@b6-ppa-7-1061] Increasing the survival time and improving the quality of life (QOL) of patients with cervical cancer has become a priority task for gynecologic oncologists.

QOL assessment can be a useful tool for determining the outcomes of treatment for cervical cancer and aiding decisions regarding further therapy. However, a major drawback for the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QLQ) core questionnaire (C30) to evaluate treatment options for cervical cancer has been the unavailability of EORTC QLQ-C30 to measure QOL issues specific to cervical cancer and its treatment as a valid and concise instrument. The EORTC QLQ cervical cancer module (CX24) aims to fill that gap. Although the EORTC QLQ-CX24 has been field-tested for psychometric properties in a multi-country study including Europe, South Korea, South Africa, and others, with satisfactory validity and reliability, patients from the People's Republic of China were not included.[@b7-ppa-7-1061]--[@b9-ppa-7-1061] The diversity between Chinese and Western culture results in different interpretations of QOL, so it is important to assess the validity, reliability, and acceptability of the EORTC QLQ-CX24 in the People's Republic of China.

Materials and methods
=====================

Participants
------------

One hundred fifteen outpatients suffering from cervical cancer in the First Affiliated Hospital of Xinxiang Medical University, Weihui, People's Republic of China were contacted between May 2013 and July 2013. All patients were over 18 years old with the ability to understand and answer survey questions, and had been pathologically diagnosed with cervical cancer. Patients who were diagnosed with a cognitive disorder or psychonosema were excluded.

Instruments
-----------

### EORTC QLQ-CX24

The EORTC QLQ-CX24 contains 24 items that can be summarized in three multi-item scales, namely, symptom experience (eleven items), body image (three items), and sexual/vaginal functioning (four items). The other dimensions of the questionnaire are single-item scales, covering lymphedema, peripheral neuropathy, menopausal symptoms, sexual worry, sexual activity, and sexual enjoyment.[@b8-ppa-7-1061] The standard scoring algorithm recommended by the EORTC is used to linearly transform all scales and item scores to a 0--100 scale, with a higher score representing a better level of functioning (for items on sexual activity and sexual enjoyment) and a higher level of symptoms (for all other items and scales).[@b10-ppa-7-1061]

### EORTC QLQ-C30

The 30-item EORTC QLQ-C30 is a psychometrically robust, cross-culturally accepted questionnaire that was designed to be applicable to a broad spectrum of cancer patients as a core questionnaire. It is classified into 15 domains including five functional subscales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning); three multi-item symptom subscales (fatigue, nausea/vomiting, and pain); a global QOL subscale; and six single items addressing various symptoms and perceived financial impact.[@b11-ppa-7-1061] All EORTC QLQ-C30 items use a four-point Likert scale (ie, "not at all," "a little," "quite a bit," and "very much"), except the two items assessing global QOL (item 29 and item 30), which use a seven-point scale.

### Karnofsky Performance Scale (KPS)

The KPS, which is used to measure performance status, is an evaluation based on the observations of physicians. The health condition of patients is evaluated using a total score of 100 that is based on three aspects: daily activities, state of illness, and degree of personal care. The Karnofsky score runs from 100 to 0, where 100 is "perfect" health and 0 is death. Practitioners occasionally assign performance scores in between standard intervals of 10.

Investigation and statistical analyses
--------------------------------------

The participating investigators were nurses on duty in relevant departments, who had already been trained to do the investigation. The investigators explained the trial and scale to the patients and obtained basic information and KPS scores from those who agreed to participate in the study and met the inclusion criteria. Each participant answered the EORTC QLQ-CX24 and EORTC QLQ-C30 independently.

Descriptive statistics were used to analyze sociodemographic and clinical data. Internal consistency reliability was determined by Cronbach's α coefficient for each dimension, and α ≥0.7 indicated adequate scale reliability. The scale structure was evaluated by multitrait scaling analysis. The convergent validity for each scale was evaluated by assessing the Pearson's correlation coefficient between each item and its own scale, while the discriminant validity was examined by comparing the Pearson's correlation coefficient of each item with other scales. Scaling errors were defined as cases in which an item correlated significantly less with its own scale than with other scales. Difference of EORTC QLQ-CX24 scores in different International Federation of Gynecology and Obstetrics (FIGO)[@b12-ppa-7-1061] stages (stage I vs stages II--IV) was analyzed by Mann--Whitney *U* test, and a *P*-value of \<0.05 was considered statistically significant. Acceptability was evaluated through the accomplishment ratio of questionnaires, missing ratio of each item, and mean time of answering questionnaires. All data were analyzed with SPSS software (v 17.0; IBM Corporation, Armonk, NY, USA).

Ethics
------

This study was approved by the institutional review board of the First Affiliated Hospital of Xinxiang Medical University. Before the survey, participants were asked to sign informed consent to identify their willingness to take part in this study and to ensure their rights of voluntary participation and privacy.

Results
=======

Sociodemographic characteristics
--------------------------------

Baseline sociodemographic characteristics for the 115 cervical cancer patients are shown in [Table 1](#t1-ppa-7-1061){ref-type="table"}. The mean age of participants was 44.8 ± 9.0 years. One hundred ten (95.7%) patients were of Han nationality and the remaining five (4.3%) patients were of other nationalities. Of all participants, 110 (95.7%) were married. Eighty (69.6%) patients had finished high school at most, and 30 (26.1%) patients held a bachelor's degree. A diagnosis of FIGO stage I disease had been made in 72 (62.6%) patients, and the remaining 43 (37.4%) patients were diagnosed in stages II--IV.

Validity and reliability
------------------------

### Multitrait scaling analyses

Results for multitrait scaling analysis are shown in [Table 2](#t2-ppa-7-1061){ref-type="table"}. Although the symptom experience scale exhibited three (3.4%) scaling errors, the scale evidenced good item-convergence (*r* =0.14--0.84) as well as item-discriminance (*r* =0.00--0.78). The body image and sexual/vaginal functioning scales exhibited 100% item-convergence (*r* =0.82--0.87 and 0.70--0.86, respectively) and 100% item-discriminance (*r* =0.03--0.76 and 0.00--0.30, respectively).

### Relationship between the EORTC QLQ-C30 and the EORTC QLQ-CX24

The symptom experience, body image, menopausal symptoms, and peripheral neuropathy scales correlated strongly with the EORTC QLQ-C30 functioning scales (*r* =0.823, 0.724, 0.762 and 0.739, respectively). The peripheral neuropathy scale correlated strongly with the physical functioning, emotional functioning, and cognitive functioning scales. Meanwhile, scales related to sexuality (the sexual/vaginal functioning, sexual worry, and sexual enjoyment scales) correlated weakly with the EORTC QLQ-C30 (*r* \<0.4), except for a moderate correlation between the sexual activity scale and EORTC QLQ-C30 (*r* =0.524) ([Table 3](#t3-ppa-7-1061){ref-type="table"}).

### Comparisons between KPS scores of EORTC QLQ-CX24 in different FIGO stages

All patients were divided into two groups based on their FIGO stage: early cervical cancer (stage I) and progressive cervical cancer (stage II--IV). As shown in [Table 4](#t4-ppa-7-1061){ref-type="table"}, only the menopausal symptom scale was capable of discriminating among patients with different FIGO stages (*P*=0.018). No significant difference of scores for patients with different FIGO stages was found in other scales of the EORTC QLQ-CX24 (*P*\>0.05). Results differed significantly among patients in early-stage (stage I) and advanced-stage (stages II--IV) with regard to peripheral neuropathy, menopausal symptoms, sexual activity, and sexual worry scales. Scores of the peripheral neuropathy and menopausal symptoms scales for patients with progressive cervical cancer were higher than for those with early cervical cancer, suggesting that correlative symptoms were much more obvious with the progression of cervical cancer. Meanwhile, the significantly lower scores of the sexual activity and sexual worry scales for patients in progressive stage compared to patients in early stage indicated that sexual activity decreased and sexual worry increased with the development of cervical cancer (data not shown).

Acceptability
-------------

The two questionnaires were easily understood, with moderate compliance, which was likely due to the importance of privacy to the women. No missing value existed in the symptom experience, body image, lymphedema, and peripheral neuropathy scales. Seven (6.1%) patients did not complete the sexual activity scale; 58 (50.4%) patients did not complete the sexual enjoyment scale; and 52 (45.2%) patients did not complete the sexual/virginal functioning scale. The mean time (± standard deviation) needed to complete assessments was 8.06 ± 4.01 minutes.

Discussion
==========

This study presents data from the translation and validation of the EORTC QLQ-C30 and the EORTC QLQ-CX24. It is the first study to perform a psychometric validation of the EORTC QLQ-CX24 in mainland China, wherein one-third of the world's new cases of cervical cancer occur annually. The evaluation of QOL has been proven to be the most essential method by which to examine therapeutic effects, and previous QOL evaluations for cervical cancer patients have been carried out in a number of countries.[@b7-ppa-7-1061],[@b9-ppa-7-1061],[@b14-ppa-7-1061] The main reason why this study is important is the fact that the morbidity and survival rate of cervical cancer is increasing, which will lead to an increase in the need for tools able to assess QOL in those cervical cancer patients. What is more, the results show that the EORTC QLQ-C30 and the EORTC QLQ-CX24, with appropriate translation, are cross-culturally valid in countries with non-English-speaking populations.

Pearson correlation analyses confirmed the satisfactory convergent and discriminant validity of the EORTC QLQ-CX24. The internal consistency of the body image scale in this study (α =0.80) was in accordance with that in previous research (α \>0.7),[@b7-ppa-7-1061],[@b8-ppa-7-1061],[@b13-ppa-7-1061],[@b14-ppa-7-1061] excluding one study conducted in South Asia by Jayasekara et al (α =0.63).[@b9-ppa-7-1061] Results of multitrait scaling analysis in our study only revealed scaling errors in the symptom experience scale, which was similar to findings in Jayasekara et al's research,[@b9-ppa-7-1061] demonstrating that EORTC QLQ-CX24 presents satisfactory reliability as well as convergent and discriminant validity in the People's Republic of China.

As [Table 4](#t4-ppa-7-1061){ref-type="table"} shows, only the menopausal symptoms scale in EORTC QLQ-CX24 was able to distinguish patients in different FIGO stages. Quite different results were obtained by Greimel et al[@b8-ppa-7-1061] -- a difference that may result from diverse attitudes toward sexuality in Eastern and Western countries. Chinese patients with cervical cancer tend to avoid talking about sexuality, so scales related to sexuality do not differentiate patients in different FIGO stages in the People's Republic of China. Another explanation might be the fact that, during the interviews, a significant group of patients seemed to focus mainly on the fact of having cancer and not on the FIGO stages. These two reasons might have made it hard for EORTC QLQ-CX24 to distinguish patients in different stages.

Correlations between the QLQ-C30 and the QLQ-CX24 were strong in some scales, which signifies clinical overlap, and weak or absent in others, which signifies differences due to the fact that both instruments assess different aspects of QOL. There is no point in using the EORTC QLQ-CX24 if the two questionnaires correlate strongly in every item, meaning that the same aspect of QOL is evaluated. These results support the EORTC statement that the questionnaires have to be used together to fully assess the QOL in patients.[@b8-ppa-7-1061]

The EORTC QLQ-CX24 proved to be patient-friendly, as evidenced by the high response rate of the study and acceptable rate of missing values. In fact, most patients welcomed the opportunity to report their health and illness experiences in detail, especially during the acute phase of their disease, perhaps to compensate for the little time they get to communicate with health care providers in the local system. There are two optional scales -- sexual/vaginal functioning and sexual enjoyment -- that can be skipped if the woman considers herself to have been not sexually active during the past 4 weeks. These scales, therefore, had a higher missing value rate than the others (50.4% and 45.2%, respectively). Other missing values for non-optional items occurred only in the sexuality scales. Similar missing values were found in foreign studies, especially in South Korea, which may due to the privacy of sexuality.[@b2-ppa-7-1061] Although patients may wish to know their physical status and assist doctors in selecting proper therapy, there remains a strong tendency to maintain sexual privacy, especially in Asian women. In order to evaluate the QOL of patients exactly, detailed interpretation of security and sexuality for patients when disseminating questionnaires is of great importance.

Prior to our study, only two papers related to the QOL of cervical cancer patients in mainland China were published, which used the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx) questionnaires.[@b15-ppa-7-1061],[@b16-ppa-7-1061] The use of FACT-Cx is more popular in the United States. Whether to favor the EORTC QLQ-CX24 or FACT-Cx in clinical practice is still in dispute.[@b17-ppa-7-1061]

Conclusion
==========

The satisfactory participation rate indicates that the Chinese version of the EORTC QLQ-CX24 questionnaire possesses ideal acceptability, and results of Cronbach's α coefficients, Pearson correlation test, and Mann--Whitney *U* test support good validity and reliability. Our results indicate that the Chinese version of the EORTC QLQ-CX24 questionnaire can be used as a reliable and efficient instrument in clinical research to study the QOL of Chinese patients with cervical cancer.
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###### 

Demographic and clinical characteristics of cervical cancer patients (n=115)

  Characteristic                                 No of patients   \%
  ---------------------------------------------- ---------------- ------
  Age (years)                                                     
   Mean ± SD                                     44.8 ± 9.0       
  Nationality                                                     
   Han                                           110              95.7
   Other                                         5                4.3
  Marriage status                                                 
   Married                                       110              95.7
   Not married                                   5                4.3
  Employment status                                               
   Employed                                      75               65.2
   Unemployed                                    40               34.8
  Educational status                                              
   High school at most                           80               69.6
   Undergraduate                                 30               26.1
   Other                                         5                4.3
  Fertility status                                                
   Has children                                  110              95.7
   Has no children                               5                4.3
  Lives together with husband                                     
   Yes                                           101              87.8
   No                                            14               12.2
  Treatment                                                       
   Surgery only                                  72               62.6
   Surgery + radiotherapy                        22               19.1
   Surgery + chemotherapy                        15               13.0
   Surgery + radiotherapy + chemotherapy         6                5.2
  FIGO stage                                                      
   Stage I                                       72               62.6
   Stages II--IV                                 43               37.4
  Climacteric status while receiving treatment                    
   Climacterium                                  25               21.7
   Childbearing period                           42               36.5
   Post-menopause (age-related)                  24               20.9
   Post-menopause (treatment-related)            23               20.0
   Unknown                                       1                0.9

**Abbreviations:** FIGO, International Federation of Gynecology and Obstetrics; SD, standard deviation.

###### 

Multitrait scaling analyses with Pearson correlations between scale items on EORTC QLQ-CX24

  Scale/items                  Item no              Mean ± SD       Cronbach's α   Item/own scalecorrelation   Item/other scale correlation   Scaling error (%)
  ---------------------------- -------------------- --------------- -------------- --------------------------- ------------------------------ -------------------
  Symptom experience           31--37, 39, 41--43   9.62 ± 10.48    0.82           0.14--0.84                  0.00--0.78                     3 (3.4)
  Body image                   45--47               16.43 ± 21.04   0.80           0.82--0.87                  0.03--0.76                     0 (0)
  Sexual/vaginal functioning   50--53               17.14 ± 19.41   0.78           0.70--0.86                  0.00--0.30                     0 (0)
  Lymphedema                   38                   7.25 ± 17.00    NA             NA                          0.03--0.63                     NA
  Peripheral neuropathy        40                   17.40 ± 19.42   NA             NA                          0.02--0.61                     NA
  Menopausal symptoms          44                   20.17 ± 23.72   NA             NA                          0.22--0.57                     NA
  Sexual worry                 48                   11.60 ± 28.97   NA             NA                          0.02--0.37                     NA
  Sexual activity              49                   28.63 ± 35.98   NA             NA                          0.02--0.37                     NA
  Sexual enjoyment             54                   38.46 ± 28.30   NA             NA                          0.03--0.50                     NA

**Note:** Cronbach's α ≥0.7 indicates adequate scale reliability.

**Abbreviations:** EORTC QLQ-CX24, European Organization for Research and Treatment of Cancer Quality of Life questionnaire cervical cancer module; NA, not applicable; SD, standard deviation.

###### 

Pearson correlations between the EORTC QLQ-C30 and the EORTC QLQ-CX24

  EORTC QLQ-C30             EORTC QLQ-CX24                                                                                                                                                                                                                                                                                                                                                                                     
  ------------------------- ----------------------------------------------------- ----------------------------------------------------- -------- ----------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------
  Functioning scales                                                                                                                                                                                                                                                                                                                                                                                                           
   Physical functioning     −0.716[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.615[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   0.009    −0.564[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.427[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.512[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   0.005                                                 0.310[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.309[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}
   Role functioning         −0.573[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.428[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   0.092    −0.340[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.714[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.425[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   0.175                                                 0.323[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.244[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}
   Emotional functioning    −0.738[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.654[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   0.012    −0.793[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.636[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.662[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   0.001                                                 0.202[\*](#tfn4-ppa-7-1061){ref-type="table-fn"}      −0.053
   Cognitive functioning    −0.824[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.573[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.026   −0.707[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.654[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.673[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   0.012                                                 0.281[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.187[\*](#tfn4-ppa-7-1061){ref-type="table-fn"}
   Social functioning       −0.572[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.724[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   0.031    −0.604[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.336[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.473[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   0.097                                                 0.363[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.102
   Global QOL               −0.553[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.583[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.036   −0.584[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.467[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.516[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   0.027                                                 0.524[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.383[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}
  Symptom scales                                                                                                                                                                                                                                                                                                                                                                                                               
   Fatigue                  0.632[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.347[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.036    0.515[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.482[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.506[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.205[\*](#tfn4-ppa-7-1061){ref-type="table-fn"}      −0.220[\*](#tfn4-ppa-7-1061){ref-type="table-fn"}     −0.125
   Nausea/vomiting          0.156                                                 0.443[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.109    0.511[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    −0.069                                                0.371[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    −0.057                                                −0.206[\*](#tfn4-ppa-7-1061){ref-type="table-fn"}     0.152
    Pain                    0.823[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.549[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    −0.004   0.551[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.739[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.603[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    −0.086                                                −0.292[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.032
  Single-item scales                                                                                                                                                                                                                                                                                                                                                                                                           
   Dyspnea                  0.660[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.375[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    −0.008   0.467[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.532[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.483[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.138                                                 −0.213[\*](#tfn4-ppa-7-1061){ref-type="table-fn"}     −0.202[\*](#tfn4-ppa-7-1061){ref-type="table-fn"}
   Insomnia                 0.558[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.442[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.000    0.518[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.466[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.762[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    −0.240[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.374[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.158
   Appetite loss            0.271[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.590[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.004    0.461[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.082                                                 0.425[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    −0.175                                                −0.437[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   −0.020
   Constipation             0.357[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.180                                                 −0.065   0.113                                                 0.548[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.506[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    −0.198[\*](#tfn4-ppa-7-1061){ref-type="table-fn"}     −0.169                                                −0.096
   Diarrhea                 0.434[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.534[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.139    0.546[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.185[\*](#tfn4-ppa-7-1061){ref-type="table-fn"}      0.083                                                 0.512[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    −0.006                                                0.119
   Financial difficulties   0.367[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.724[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    −0.005   0.643[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.435[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    0.378[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}    −0.029                                                −0.328[\*\*](#tfn5-ppa-7-1061){ref-type="table-fn"}   0.015

**Notes:**

Correlation is significant at the 0.05 level (\<0.40 =weak correlation, 0.40--0.60 =moderate correlation, \>0.60 =high correlation).

Correlation is significant at the 0.01 level (two-tailed).

**Abbreviations:** C30, core questionnaire; CX24, cervical cancer module; EORTC, European Organization for Research and Treatment of Cancer; QLQ, Quality of Life questionnaire; QOL, quality of life.

###### 

Comparisons between Karnofsky Performance Scale scores of EORTC QLQ-CX24 in different FIGO stages

  EORTC QLQ-CX24 scale          Mean ± SD       *P*[\*](#tfn7-ppa-7-1061){ref-type="table-fn"}   
  ----------------------------- --------------- ------------------------------------------------ -------
  Multi-item scales                                                                              
   Symptom experience           9.64 ±10.07     9.58 ± 11.24                                     0.656
   Body image                   13.73 ± 19.06   20.93 ± 23.53                                    0.152
   Sexual/vaginal functioning   15.36 ± 18.10   20.00 ± 21.53                                    0.458
  Single-item scales                                                                             
   Lymphedema                   5.09 ± 14.44    10.85 ± 20.21                                    0.072
   Peripheral neuropathy        15.28 ± 19.33   20.93 ± 19.28                                    0.104
   Menopausal symptoms          16.43 ± 23.14   26.36 ± 23.66                                    0.018
   Sexual activity              32.84 ± 38.84   24.17 ± 30.18                                    0.391
   Sexual worry                 13.89 ± 32.02   7.75 ± 22.81                                     0.405
   Sexual enjoyment             35.35 ± 29.98   43.86 ± 24.98                                    0.338

**Note:**

Mann--Whitney *U* test.

**Abbreviations:** EORTC QLQ-CX24, European Organization for Research and Treatment of Cancer Quality of Life questionnaire cervical cancer module; FIGO, International Federation of Gynecology and Obstetrics; SD, standard deviation.
